
|Videos|March 1, 2022
Dr. Dason on “not favoring” treatments for UTUC patients post-nephroureterectomy
Author(s)Urology Times staff
“Multidisciplinary discussion is best,” says Shawn Dason, MD, FRCSC.
Advertisement
In this video, Shawn Dason, MD, FRCSC, discusses the takeaways of the study, “How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?” This study was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
High PHI scores are linked to increased odds of significant prostate cancer
2
Trial to evaluate novel combination in BCG-unresponsive NMIBC
3
Dosing begins in trial of alpha radioligand therapy for mCRPC
4
FDA grants fast track designation to Enolen for localized prostate cancer
5




















